Bristol Myers Squibb (NYSE:BMY) Upgraded to “Strong-Buy” at Barclays

Bristol Myers Squibb (NYSE:BMY) was upgraded by equities research analysts at Barclays to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

BMY has been the topic of several other reports. UBS Group upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the stock from $46.00 to $65.00 in a research note on Wednesday, January 7th. HSBC restated a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 target price (up previously from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Finally, Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $52.00 to $61.00 in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $60.19.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $60.66 on Thursday. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $63.33. The business’s fifty day simple moving average is $56.22 and its 200 day simple moving average is $49.97. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm has a market capitalization of $123.53 billion, a P/E ratio of 17.58, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts anticipate that Bristol Myers Squibb will post 6.74 EPS for the current year.

Hedge Funds Weigh In On Bristol Myers Squibb

Several large investors have recently modified their holdings of the stock. Brighton Jones LLC increased its holdings in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC increased its stake in shares of Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares during the period. United Bank raised its holdings in shares of Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Brookstone Capital Management lifted its stake in Bristol Myers Squibb by 3.5% in the second quarter. Brookstone Capital Management now owns 40,127 shares of the biopharmaceutical company’s stock worth $1,858,000 after acquiring an additional 1,358 shares during the period. Finally, AlTi Global Inc. lifted its stake in Bristol Myers Squibb by 12.2% in the second quarter. AlTi Global Inc. now owns 4,420 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 482 shares during the period. Institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.